Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.

@article{Sittl2005ChangesIT,
  title={Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.},
  author={Reinhard Sittl and Mark Nuijten and Barbara Poulsen Nautrup},
  journal={Clinical therapeutics},
  year={2005},
  volume={27 7},
  pages={1022-31}
}
BACKGROUND During long-term therapy with strong opioids (step III opioids according to the World Health Organization [WHO] analgesic ladder), dose increases are often necessary because of deterioration of the primary disease or development of tolerance. OBJECTIVE The purpose of this study was to compare changes in dosages of transdermal (TD) fentanyl and TD buprenorphine in patients with cancer and non-cancer pain. METHODS In a retrospective study, patients with cancer and noncancer pain… CONTINUE READING